Trial Profile
Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/carboplatin, in patients with metastatic Triple Negative Breast Cancer (mTNBC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Iniparib (Primary) ; Carboplatin; Gemcitabine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Jul 2012 Planned end date changed from 1 Jun 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 28 Feb 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 19 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.